CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: GPN2 (ImmuneEditome ID:54707)

1. Gene summary of enriched editing regions for GPN2

check button Gene summary
Gene informationGene symbol

GPN2

Gene ID

54707

GeneSynonymsATPBD1B
GeneCytomap

1p36.11

GeneTypeprotein-coding
GeneDescriptionGPN-loop GTPase 2|ATP-binding domain 1 family member B
GeneModificationdate20230329
UniprotIDQ9H9Y4;Q5JYG4;Q5JYG3
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:26878309-26879192:-ENST00000374135.7ENSG00000142751.13GPN2UTR3AluSx,AluSc,FLAM_A,MER113chr1:26878309-26879192:-.alignment
chr1:26880392-26882311:-ENST00000477418.2ENSG00000142751.13GPN2ncRNA_intronicAluSq2,AluSc5,AluJb,AluJr,AluJo,L2c,MER47Achr1:26880392-26882311:-.alignment
chr1:26883590-26884032:-ENST00000477418.2ENSG00000142751.13GPN2ncRNA_intronicAluY,AluSq2chr1:26883590-26884032:-.alignment


Top

2. Tumor-specific enriched editing regions for GPN2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:26878309-26879192:-KICHEER5.3421e-05image
ENSG00000142751.13,GPN2KICHEAG4.2056e-05image
chr1:26878309-26879192:-KIRCEER4.0714e-02image
ENSG00000142751.13,GPN2KIRCEAG4.0295e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr1:26878309-26879192:-CESCCliEER9.2293e-031.2694e-020.1755image
ENSG00000142751.13,GPN2CESCCliEAG1.8821e-022.7932e-020.1539image
chr1:26878309-26879192:-READPathEER4.8930e-021.3659e-020.3822image
chr1:26878309-26879192:-THCAPathEER3.5999e-021.4934e-020.1142image
ENSG00000142751.13,GPN2THCAPathEAG3.7249e-028.2419e-030.1237image
chr1:26878309-26879192:-UCECCliEER2.3580e-034.7963e-020.1681image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000142751.13,GPN2LIHCEAG4.9234e-028.9271e-034.9718e-02image

Top

3. Enriched editing regions and immune related genes for GPN2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:26878309-26879192:-PAADEERENSG00000110060,PUS3-0.37084.3362e-031.3362e-06-0.4063imageNIGF2BP2;TAF15NAMacrophages_M0GSVA_HALLMARK_MYC_TARGETS_V1
chr1:26878309-26879192:-PAADEERENSG00000131591,C1orf1590.33481.2764e-021.8999e-060.4009imageNIGF2BP2;TAF15NAMacrophages_M0GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:26878309-26879192:-PAADEERENSG00000057149,SERPINB30.29482.8615e-024.2871e-070.4232imageNTAF15NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr1:26878309-26879192:-PAADEERENSG00000064932,SBNO20.27734.9628e-021.3151e-060.4066imageNIGF2BP2;TAF15SBNO2T_cells_regulatory_(Tregs)GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:26878309-26879192:-THYMEERENSG00000130312,MRPL340.50949.9091e-061.2837e-070.5102imageNIGF2BP2;TAF15NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr1:26878309-26879192:-THYMEERENSG00000100442,FKBP30.45401.1049e-043.7617e-070.4934imageNIGF2BP2;TAF15FKBP3T_cells_follicular_helperGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr1:26878309-26879192:-THYMEERENSG00000176182,MYPOP0.44561.3107e-041.2400e-050.4319imageNIGF2BP2;TAF15NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEDGEHOG_SIGNALING
chr1:26878309-26879192:-THYMEERENSG00000070010,UFD1L0.43591.4957e-042.5078e-050.4179imageNIGF2BP2;TAF15NAT_cells_follicular_helperGSVA_HALLMARK_TGF_BETA_SIGNALING
chr1:26878309-26879192:-THYMEERENSG00000049656,CLPTM1L0.43981.6876e-044.5760e-050.4055imageNIGF2BP2;TAF15CLPTM1LT_cells_regulatory_(Tregs)GSVA_HALLMARK_E2F_TARGETS
chr1:26878309-26879192:-THYMEERENSG00000242498,ARPIN-0.44222.1315e-043.1566e-05-0.4132imageNIGF2BP2;TAF15NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

4. Enriched editing regions and immune related splicing for GPN2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000142751.13,GPN2
ESCAEAGIRENSG00000185567.6chr14104937243:104950665:104952150:104952201-0.23174.8524e-023.3556e-05-0.4022imageNADAR;CNBP;CSTF2T;DDX54;DGCR8;DICER1;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;IGF2BP1;IGF2BP2;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;NONO;NOP56;NOP58;PTBP1;RBFOX2;RBM10;SLTM;SMNDC1;SRSF1;SRSF3;TAF15;TIA1;TIAL1;TRA2A;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184NAGSVA_HALLMARK_HYPOXIA
ENSG00000142751.13,GPN2
ESCAEAGESENSG00000070269.9chr1456615943:56616027:56617182:56617297:56618593:56618663-0.37441.1473e-029.3954e-07-0.4117imageNADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RC3H1;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184NAMacrophages_M1GSVA_HALLMARK_BILE_ACID_METABOLISM
chr1:26878309-26879192:-
KIRCEERMEXENSG00000089289.11chrX70134522:70134816:70146632:70146828:70150195:70150322:70165832:70166324-0.31281.5196e-055.2604e-13-0.4002imageNIGF2BP2;TAF15IGBP1T_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr1:26878309-26879192:-
KIRCEERMEXENSG00000089289.11chrX70134522:70134816:70146632:70146828:70150209:70150322:70165832:70166324-0.31281.5226e-055.3067e-13-0.4002imageNIGF2BP2;TAF15IGBP1T_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000142751.13,GPN2
KIRCEAGMEXENSG00000089289.11chrX70134522:70134816:70146632:70146828:70150195:70150322:70165832:70166324-0.32047.7936e-063.0691e-13-0.4033imageNADAR;BCCIP;BUD13;CAPRIN1;CBX7;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAGIGBP1T_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000142751.13,GPN2
KIRCEAGMEXENSG00000089289.11chrX70134522:70134816:70146632:70146828:70150209:70150322:70165832:70166324-0.32047.8125e-063.0922e-13-0.4032imageNADAR;BCCIP;BUD13;CAPRIN1;CBX7;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAGIGBP1T_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr1:26878309-26879192:-
THYMEERA3ENSG00000134575.5chr1147242722:47242898:47240085:47240166:47240085:472402490.40095.1508e-037.7019e-070.4818imageNIGF2BP2;TAF15NAT_cells_CD4_memory_activatedGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
chr1:26878309-26879192:-
THYMEERIRENSG00000152076.14chr2130142100:130142183:130143268:130143313-0.32471.9375e-023.4313e-04-0.4051imageNIGF2BP2;TAF15NAMonocytesGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000142751.13,GPN2
THYMEAGA5ENSG00000122678.10chr744073988:44074025:44074397:44074522:44074130:44074522-0.42094.0662e-035.6774e-06-0.4467imageNADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMast_cells_restingGSVA_HALLMARK_NOTCH_SIGNALING
chr1:26878309-26879192:-
THYMEERESENSG00000089597.12chr1162633444:62633514:62634309:62634375:62634820:62635000-0.36891.0326e-021.5525e-05-0.4452imageNIGF2BP2;TAF15NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ANGIOGENESIS

More results



Top

5. Enriched editing regions and immune infiltration for GPN2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:26878309-26879192:-ACCEERMast_cells_resting2.5713e-02-0.3034image
ENSG00000142751.13,GPN2ACCEAGMast_cells_resting2.3682e-02-0.3047image
chr1:26878309-26879192:-BLCAEERNK_cells_resting1.9136e-020.1512image
ENSG00000142751.13,GPN2BLCAEAGT_cells_CD4_naive2.5318e-02-0.1444image
chr1:26878309-26879192:-BRCAEERNK_cells_activated1.8905e-040.1292image
chr1:26883590-26884032:-BRCAEERT_cells_CD4_memory_activated2.6797e-030.5285image
ENSG00000142751.13,GPN2BRCAEAGNK_cells_activated3.8228e-040.1227image
chr1:26878309-26879192:-CESCEERT_cells_follicular_helper1.3517e-020.1723image
ENSG00000142751.13,GPN2CESCEAGT_cells_follicular_helper4.4725e-030.1964image
ENSG00000142751.13,GPN2CHOLEAGNK_cells_resting8.2824e-060.8232image
chr1:26878309-26879192:-COADEERMacrophages_M13.0850e-02-0.2006image
ENSG00000142751.13,GPN2COADEAGMacrophages_M18.5876e-03-0.2379image
chr1:26878309-26879192:-DLBCEERMacrophages_M23.6238e-030.5931image
ENSG00000142751.13,GPN2DLBCEAGMonocytes4.0392e-030.5875image
chr1:26878309-26879192:-ESCAEERMacrophages_M12.1251e-030.2558image
chr1:26883590-26884032:-ESCAEERT_cells_regulatory_(Tregs)4.1540e-02-0.2733image
ENSG00000142751.13,GPN2ESCAEAGMacrophages_M11.0132e-030.2730image
chr1:26878309-26879192:-GBMEERPlasma_cells9.3799e-050.3125image
ENSG00000142751.13,GPN2GBMEAGPlasma_cells1.0613e-040.3102image
chr1:26878309-26879192:-KICHEERB_cells_naive1.8625e-030.4421image
ENSG00000142751.13,GPN2KICHEAGB_cells_naive1.8249e-030.4385image
chr1:26878309-26879192:-KIRCEERT_cells_regulatory_(Tregs)4.3677e-040.2015image
ENSG00000142751.13,GPN2KIRCEAGT_cells_regulatory_(Tregs)1.8948e-040.2132image
chr1:26878309-26879192:-KIRPEERNeutrophils1.9529e-040.2772image
ENSG00000142751.13,GPN2KIRPEAGNeutrophils3.1798e-040.2683image
ENSG00000142751.13,GPN2LAMLEAGT_cells_gamma_delta4.2699e-040.4751image
chr1:26878309-26879192:-LGGEERT_cells_CD4_naive4.7967e-040.1559image
ENSG00000142751.13,GPN2LGGEAGT_cells_CD4_naive6.2508e-040.1528image
chr1:26878309-26879192:-LUADEERMacrophages_M04.3292e-020.1204image
chr1:26878309-26879192:-LUSCEERMacrophages_M02.4545e-020.1578image
ENSG00000142751.13,GPN2LUSCEAGMacrophages_M01.0544e-020.1766image
chr1:26878309-26879192:-MESOEERT_cells_regulatory_(Tregs)2.1955e-02-0.3004image
ENSG00000142751.13,GPN2MESOEAGT_cells_regulatory_(Tregs)2.3159e-02-0.2978image
chr1:26878309-26879192:-OVEERT_cells_gamma_delta4.5432e-030.2465image
ENSG00000142751.13,GPN2OVEAGT_cells_gamma_delta5.4889e-030.2360image
chr1:26878309-26879192:-PAADEERT_cells_CD4_memory_activated3.5558e-02-0.1831image
ENSG00000142751.13,GPN2PAADEAGT_cells_CD4_memory_activated3.2274e-02-0.1865image
chr1:26878309-26879192:-PCPGEERNK_cells_activated3.0220e-02-0.2022image
ENSG00000142751.13,GPN2PCPGEAGNK_cells_activated2.5324e-02-0.2085image
chr1:26878309-26879192:-PRADEERT_cells_CD81.1463e-030.1595image
chr1:26880392-26882311:-PRADEERNK_cells_activated1.6004e-020.3883image
ENSG00000142751.13,GPN2PRADEAGT_cells_CD82.0328e-030.1509image
chr1:26878309-26879192:-SKCMEERMast_cells_resting7.3999e-030.1506image
ENSG00000142751.13,GPN2SKCMEAGMast_cells_resting7.3234e-030.1506image
chr1:26880392-26882311:-STADEERT_cells_CD4_naive1.5184e-020.2977image
chr1:26883590-26884032:-STADEERMacrophages_M03.1972e-02-0.2585image
chr1:26878309-26879192:-TGCTEERDendritic_cells_activated3.0575e-020.2467image
ENSG00000142751.13,GPN2TGCTEAGDendritic_cells_activated3.0386e-020.2469image
chr1:26878309-26879192:-THCAEEREosinophils3.1634e-030.1379image
chr1:26883590-26884032:-THCAEERB_cells_memory2.7715e-020.3953image
ENSG00000142751.13,GPN2THCAEAGEosinophils9.2554e-030.1216image
chr1:26878309-26879192:-THYMEERT_cells_regulatory_(Tregs)1.0877e-030.3301image
ENSG00000142751.13,GPN2THYMEAGT_cells_regulatory_(Tregs)1.2909e-030.3254image
ENSG00000142751.13,GPN2UCECEAGMacrophages_M24.1656e-020.2152image
chr1:26878309-26879192:-UVMEERT_cells_CD88.8853e-03-0.4135image
ENSG00000142751.13,GPN2UVMEAGT_cells_CD89.8388e-03-0.4084image


Top

6. Enriched editing regions and immune gene sets for GPN2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr1:26878309-26879192:-ESCAEER1.1892e-040.31741.3982e-020.20581.0941e-040.31904.8014e-020.1662image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr1:26878309-26879192:-ACCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.4929e-02-0.3050image
ENSG00000142751.13,GPN2ACCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.0740e-02-0.3112image
chr1:26883590-26884032:-BRCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER4.9938e-030.4991image
chr1:26878309-26879192:-BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER8.2860e-100.2110image
ENSG00000142751.13,GPN2BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.7368e-100.2163image
ENSG00000142751.13,GPN2COADGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.7126e-03-0.2822image
chr1:26878309-26879192:-COADGSVA_HALLMARK_PROTEIN_SECRETIONEER4.2320e-03-0.2637image
chr1:26878309-26879192:-DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.3126e-02-0.4820image
ENSG00000142751.13,GPN2DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.7799e-02-0.4264image
chr1:26883590-26884032:-ESCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER5.4162e-030.3669image
ENSG00000142751.13,GPN2ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.2320e-03-0.2455image
chr1:26878309-26879192:-ESCAGSVA_HALLMARK_MTORC1_SIGNALINGEER2.7287e-030.2497image
chr1:26878309-26879192:-GBMGSVA_HALLMARK_MITOTIC_SPINDLEEER2.1554e-04-0.2968image
ENSG00000142751.13,GPN2GBMGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.4791e-04-0.2745image
ENSG00000142751.13,GPN2HNSCGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.1212e-020.1516image
chr1:26878309-26879192:-HNSCGSVA_HALLMARK_COAGULATIONEER2.7493e-020.1463image
chr1:26878309-26879192:-KICHGSVA_HALLMARK_PROTEIN_SECRETIONEER2.6366e-020.3239image
ENSG00000142751.13,GPN2KICHGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.3973e-020.3255image
ENSG00000142751.13,GPN2KIRCGSVA_HALLMARK_HEME_METABOLISMEAG1.0887e-04-0.2208image
chr1:26878309-26879192:-KIRCGSVA_HALLMARK_HEME_METABOLISMEER1.1932e-04-0.2200image
chr1:26878309-26879192:-KIRPGSVA_HALLMARK_SPERMATOGENESISEER2.4842e-02-0.1691image
ENSG00000142751.13,GPN2KIRPGSVA_HALLMARK_G2M_CHECKPOINTEAG1.0891e-02-0.1915image
chr1:26878309-26879192:-LGGGSVA_HALLMARK_UV_RESPONSE_DNEER4.6544e-03-0.1266image
ENSG00000142751.13,GPN2LGGGSVA_HALLMARK_UV_RESPONSE_DNEAG3.8248e-03-0.1294image
ENSG00000142751.13,GPN2LIHCGSVA_HALLMARK_SPERMATOGENESISEAG2.4691e-03-0.2470image
chr1:26878309-26879192:-LIHCGSVA_HALLMARK_SPERMATOGENESISEER7.4339e-03-0.2207image
chr1:26878309-26879192:-LUADGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.6480e-030.1866image
ENSG00000142751.13,GPN2LUADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.3585e-030.1738image
ENSG00000142751.13,GPN2LUSCGSVA_HALLMARK_G2M_CHECKPOINTEAG1.4376e-02-0.1691image
chr1:26878309-26879192:-LUSCGSVA_HALLMARK_G2M_CHECKPOINTEER2.4041e-02-0.1584image
chr1:26878309-26879192:-MESOGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.9029e-030.3993image
ENSG00000142751.13,GPN2MESOGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.8858e-030.3996image
chr1:26878309-26879192:-OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.2277e-030.2794image
ENSG00000142751.13,GPN2OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.8207e-030.2641image
chr1:26878309-26879192:-PAADGSVA_HALLMARK_APICAL_JUNCTIONEER2.0069e-030.2665image
ENSG00000142751.13,GPN2PAADGSVA_HALLMARK_APICAL_JUNCTIONEAG2.8861e-030.2574image
chr1:26878309-26879192:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER1.7822e-07-0.2535image
ENSG00000142751.13,GPN2PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.2578e-08-0.2615image
chr1:26880392-26882311:-PRADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.2234e-02-0.4025image
chr1:26878309-26879192:-SARCGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.8849e-020.1500image
ENSG00000142751.13,GPN2SARCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.0109e-020.1491image
ENSG00000142751.13,GPN2SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.9342e-03-0.1469image
chr1:26878309-26879192:-SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEER1.0101e-02-0.1448image
chr1:26880392-26882311:-STADGSVA_HALLMARK_NOTCH_SIGNALINGEER3.1269e-030.3584image
ENSG00000142751.13,GPN2STADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.1603e-020.1465image
chr1:26878309-26879192:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.2983e-020.1460image
chr1:26883590-26884032:-STADGSVA_HALLMARK_G2M_CHECKPOINTEER2.6576e-02-0.2670image
ENSG00000142751.13,GPN2TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.8984e-02-0.2358image
chr1:26878309-26879192:-TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEER3.8645e-02-0.2362image
chr1:26883590-26884032:-THCAGSVA_HALLMARK_MITOTIC_SPINDLEEER3.5937e-02-0.3782image
chr1:26878309-26879192:-THCAGSVA_HALLMARK_MITOTIC_SPINDLEEER2.6796e-04-0.1699image
ENSG00000142751.13,GPN2THCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0250e-04-0.1807image
chr1:26878309-26879192:-THYMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.3477e-050.4303image
ENSG00000142751.13,GPN2THYMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.8846e-050.4237image
ENSG00000142751.13,GPN2UCECGSVA_HALLMARK_HEME_METABOLISMEAG4.6455e-02-0.2105image
chr1:26878309-26879192:-UVMGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER9.6357e-03-0.4095image
ENSG00000142751.13,GPN2UVMGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG9.5218e-03-0.4101image


Top

7. Enriched editing regions and drugs for GPN2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr1:26878309-26879192:-ACCEHT.1864EER1.4456e-02-0.3311image
ENSG00000142751.13,GPN2ACCEHT.1864EAG2.9563e-02-0.2936image
ENSG00000142751.13,GPN2BLCAEmbelinEAG1.5489e-020.1561image
chr1:26878309-26879192:-BLCAEmbelinEER2.2861e-020.1469image
chr1:26883590-26884032:-BRCADoxorubicinEER1.2967e-03-0.5598image
ENSG00000142751.13,GPN2BRCACCT007093EAG1.0311e-060.1682image
chr1:26878309-26879192:-BRCACCT007093EER1.0116e-060.1688image
ENSG00000142751.13,GPN2CESCImatinibEAG1.0971e-02-0.1761image
chr1:26878309-26879192:-CESCABT.888EER1.0593e-020.1782image
ENSG00000142751.13,GPN2COADABT.263EAG9.3357e-04-0.2972image
chr1:26878309-26879192:-COADABT.263EER4.9760e-04-0.3183image
ENSG00000142751.13,GPN2DLBCJNK.9LEAG1.7236e-02-0.5022image
chr1:26878309-26879192:-DLBCFH535EER2.0716e-020.4897image
ENSG00000142751.13,GPN2ESCABleomycinEAG4.4898e-04-0.2907image
chr1:26883590-26884032:-ESCAAZD.2281EER3.0771e-04-0.4648image
chr1:26878309-26879192:-ESCAEpothilone.BEER4.7722e-04-0.2894image
ENSG00000142751.13,GPN2GBMAZD6482EAG1.5405e-020.1969image
chr1:26878309-26879192:-GBMAZD6482EER6.8060e-030.2194image
ENSG00000142751.13,GPN2HNSCJNJ.26854165EAG2.0520e-03-0.2018image
chr1:26878309-26879192:-HNSCJNJ.26854165EER1.7837e-03-0.2063image
ENSG00000142751.13,GPN2KIRCJNK.9LEAG9.9400e-070.2772image
chr1:26878309-26879192:-KIRCJNK.9LEER2.6492e-070.2914image
chr1:26878309-26879192:-KIRPJNJ.26854165EER4.8713e-02-0.1488image
ENSG00000142751.13,GPN2LAMLCGP.60474EAG2.4316e-020.3151image
chr1:26878309-26879192:-LGGAZD6482EER8.2063e-050.1756image
ENSG00000142751.13,GPN2LGGAZD6482EAG2.1521e-040.1651image
ENSG00000142751.13,GPN2LIHCBryostatin.1EAG5.9599e-04-0.2790image
chr1:26878309-26879192:-LIHCAMG.706EER3.5730e-03-0.2397image
ENSG00000142751.13,GPN2LUADBMS.536924EAG3.1786e-04-0.2129image
chr1:26878309-26879192:-LUADBMS.536924EER5.9024e-05-0.2372image
chr1:26878309-26879192:-LUSCBexaroteneEER3.1325e-02-0.1512image
ENSG00000142751.13,GPN2LUSCBexaroteneEAG2.2264e-02-0.1581image
chr1:26878309-26879192:-MESOCHIR.99021EER2.4779e-02-0.2946image
ENSG00000142751.13,GPN2MESOCHIR.99021EAG2.4505e-02-0.2951image
chr1:26878309-26879192:-OVATRAEER4.9528e-040.3002image
ENSG00000142751.13,GPN2OVA.770041EAG5.8352e-04-0.2901image
ENSG00000142751.13,GPN2PAADBexaroteneEAG5.5392e-03-0.2402image
chr1:26878309-26879192:-PAADBexaroteneEER4.1956e-03-0.2477image
ENSG00000142751.13,GPN2PCPGA.770041EAG9.9304e-04-0.3044image
chr1:26878309-26879192:-PCPGA.770041EER9.9661e-04-0.3043image
ENSG00000142751.13,GPN2PRADBAY.61.3606EAG3.6237e-040.1740image
chr1:26880392-26882311:-PRADJNK.9LEER3.5846e-030.4610image
chr1:26878309-26879192:-PRADABT.263EER6.2613e-040.1676image
chr1:26878309-26879192:-READBicalutamideEER1.6236e-020.3526image
ENSG00000142751.13,GPN2READBicalutamideEAG2.0440e-020.3409image
chr1:26878309-26879192:-SARCCCT018159EER1.2221e-020.1815image
ENSG00000142751.13,GPN2SARCCCT018159EAG1.0975e-020.1842image
chr1:26880392-26882311:-STADEpothilone.BEER1.2388e-02-0.3062image
ENSG00000142751.13,GPN2STADGW843682XEAG2.9683e-02-0.1264image
chr1:26878309-26879192:-STADBortezomibEER4.2775e-02-0.1193image
chr1:26883590-26884032:-STADGSK269962AEER1.5190e-03-0.3746image
chr1:26883590-26884032:-THCAGDC.0449EER2.3462e-02-0.4059image
chr1:26878309-26879192:-THCAEmbelinEER1.6977e-060.2220image
ENSG00000142751.13,GPN2THCAEmbelinEAG5.4750e-070.2317image
chr1:26878309-26879192:-THYMAS601245EER1.3754e-050.4299image
ENSG00000142751.13,GPN2THYMAS601245EAG2.2297e-050.4203image
chr1:26878309-26879192:-UCECCEP.701EER7.9862e-03-0.2795image
ENSG00000142751.13,GPN2UCSGemcitabineEAG4.7930e-020.2901image
chr1:26878309-26879192:-UCSGemcitabineEER4.7930e-020.2901image
chr1:26878309-26879192:-UVMKU.55933EER3.2455e-040.5459image
ENSG00000142751.13,GPN2UVMKU.55933EAG3.5522e-040.5429image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType